AnGes MG enters into collaborative agreement and invests $22.6 million in Vical
Clients AnGes MG, Inc.
Jones Day advised AnGes MG, Inc. in connection with its purchase of $22.6 million of Common Stock in a private placement by Vical Incorporated.
Vical and AnGes MG, Inc. also entered into a collaborative agreement for Vical's Allovectin-7® cancer immunotherapeutic. Under the agreement, AnGes will provide up to $100 million in ongoing clinical trial funding and future sales-based milestones as Allovectin-7® is successfully commercialized. Vical retains exclusive marketing rights for Allovectin-7® in the United States and the rest of the world outside of specified Asian countries, for which AnGes received exclusive rights.